Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-05
2006-12-05
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S325000
Reexamination Certificate
active
07144861
ABSTRACT:
A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1–34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
REFERENCES:
patent: 4698328 (1987-10-01), Neer et al.
patent: 5496801 (1996-03-01), Holthuis et al.
patent: 5607915 (1997-03-01), Patton
patent: 5616560 (1997-04-01), Geddes et al.
patent: 5891086 (1999-04-01), Weston
patent: 6454746 (2002-09-01), Bydlon et al.
patent: 6582728 (2003-06-01), Platz et al.
patent: 6770623 (2004-08-01), Chang
patent: 2 234 724 (1998-04-01), None
patent: O 302 772 (1989-02-01), None
patent: 0 490 806 (1992-06-01), None
patent: 0 619 119 (1994-10-01), None
patent: WO 91/06564 (1991-05-01), None
patent: WO 94/08613 (1994-04-01), None
patent: WO 95/17207 (1995-06-01), None
patent: WO 99/5353 (1998-04-01), None
Martin et al. “Effects of Benyzl alcohol on PTh receptor-adenylate cyclase system of canine kidney”, American journal of physiology, (Jan. 1985) 248 (1 Pt 1) E31-5. 1985.
Reeve et al., “Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial”, Br. Med. J., 280(6228) :1340-1344, 1980.
Reeve et al., “Anabolic Effect of Low Doses of a Fragment of Human Parathyroid Hormone on the Skeleton in Postmenopausal Osteoporosis”, The Lancet, 1:1035-1038, 1976.
Reeve et al., “Preliminary Trial of Low Doses of Human Parathyroid Hormone 1-34 Peptide in Treatment of Osteoporosis”, Calcif. Tissue Res., 21:469-477, 1976.
Hodsman et al., “Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients”, Bone and Mineral, 9(2) :137-152, 1990.
Tsai et al., “Bone Responsiveness to Parathyroid Hormone in Normal and Osteoporotic Postmenopausal Women”, J. Clin. Endocrinol Metab., 169(5) :1024-1027, 1989.
Isaac et al., “Absence of Effect of 1-34 h PTH on Plasma TSH, GH, FSH, LH, ACTH, and Cortisol in Normal Man”, Horm. Metab. Res., 12(9) :487-488, 1980.
Law et al., “Rapid Development of Renal Resistance to Low Doses of Synthetic Bovine Parathyroid Hormone Fragment 1-34”, J. Clin Invest., 72(3) :1106-1113, 1983.
Hulter et al., “Chronic Continuous PTH Infusion Results in Hypertension in Normal Subjects”, J. Clin Hypertens, 2(4) :360-370, 1986.
Hodsman et al., “Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients”, 14(1) :67-83, 1991.
Martindale, The Extra Pharmacoepia, The Pharmaceutical Press, London, 29th Edition, 1989 p. 1338 (Copy not provided).
Chang Chin-Ming
Havel Henry A.
Barrett Brian P.
Caltrider Steven P.
Eli Lilly and Company
Gupta Anish
Webster Thomas D
LandOfFree
Stabilized teriparatide solutions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized teriparatide solutions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized teriparatide solutions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696209